Infectious disease diagnostics market seen reaching $65.49 billion by 2030

The infectious disease diagnostics testing market is projected to grow from $42.24 billion in 2025 to $65.49 billion by 2030, according to The Business Research Company. Rising respiratory infections, rapid testing demand and broader disease surveillance are among the main forces behind the expansion.

Why it matters: - The infectious disease diagnostics testing market is expanding as health systems face more respiratory infections, pandemic risk and demand for faster pathogen detection. - Faster and more accurate testing affects treatment decisions, outbreak control and public health surveillance. - The market’s projected growth suggests continued investment in diagnostic labs, molecular testing and point-of-care tools.

What happened: - The Business Research Company released its Infectious Disease Diagnostics Testing Market Report 2026 – Market Size, Trends, And Global Forecast 2026-2035 on August 12, 2026. - The report puts the market at $42.24 billion in 2025 and $46.48 billion in 2026, a 10.0% CAGR. - The market is forecast to reach $65.49 billion by 2030, with a 9.0% CAGR. - The report also says North America held the largest market share in 2025. - The Asia-Pacific region is projected to be the fastest-growing market in the coming years. - A free sample of the report is available here. - The full report is available here.

The details: - Infectious disease diagnostics testing detects bacteria, viruses, fungi or parasites in patient samples. - The tests support accurate diagnosis and treatment decisions. - The diagnostics also help control disease spread and monitor outbreaks. - The report ties recent growth to rising infectious disease prevalence, more respiratory infection cases, expansion of diagnostic labs, early-diagnosis awareness and government disease-control initiatives. - Future growth drivers include pandemic risk, demand for rapid diagnostic technologies, higher healthcare diagnostics spending, broader surveillance and a heavier tropical and viral disease burden. - The report highlights trends including rapid and early detection, wider point-of-care testing, expanded molecular diagnostics and larger screening and surveillance programs. - Regional coverage includes Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The 2026 report adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based dashboards, market hotspots infographics, and updated technology and trend analysis. - Canadian Institute for Health Information data from February 2024 showed acute upper respiratory infection hospital admissions rose 32% in 2023 to 2,797 from 2,114 in 2022.

Between the lines: - The forecast points to a market that is moving from crisis-driven demand toward more routine screening, surveillance and rapid testing use. - North America’s lead suggests mature health infrastructure still shapes market share, while Asia-Pacific growth reflects expanding access and demand. - The emphasis on molecular and point-of-care testing signals a shift toward faster, more decentralized diagnostics.

What's next: - The market is expected to keep growing through 2030 as health systems invest in faster detection and broader surveillance. - Adoption of rapid diagnostic technologies and molecular methods is likely to remain a central theme in the category. - The Business Research Company says the 2026 report includes new strategic intelligence tools for buyers and analysts.